



**Checklist for Actemra (tocilizumab) or Biosimilar Referral**

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Date: \_\_\_\_\_

Referring Physician: \_\_\_\_\_ NPI: \_\_\_\_\_

Office Contact/Title/Email: \_\_\_\_\_

Office Address: \_\_\_\_\_

Office Phone: \_\_\_\_\_ Office Fax: \_\_\_\_\_

Best contact number for physician in case of reaction: \_\_\_\_\_

*Please return completed checklist and checklist items to initiate referral. Use this form as fax cover sheet.*

- ☐ Patient demographic information
- ☐ Insurance information and copy of insurance card/s (front and back). \*Include primary and secondary insurance
- ☐ Supporting clinical notes and office visits. Two notes preferred.
  - Note should include any therapies tried/failed, and must include discussion about Actemra
  - Medication list and allergies
- ☐ Supporting lab reports/imaging for Actemra treatment
  - Baseline: Lipid panel, LFTs, neutrophils, platelets, and negative TB screening
  - *Recommended:* negative hepatitis B screening
  - For continued therapy:
    - Lipid panel 4-8 weeks after Actemra start
    - LFTs every 4-8 weeks for first 6 months after Actemra start, then every 3 months thereafter
    - Neutrophils and platelets 4-8 weeks after Actemra start, then every 3 months thereafter
- ☐ Actemra Prescribing Order (see attached)

**-- We will obtain prior authorization and schedule your patient as soon as possible --**

---

**Fax all information to our Infusion Coordinator: 508-698-8671**

Call with any questions: 781-551-5812 option 4

---

Visit our website: [www.InfusionCenterNE.com](http://www.InfusionCenterNE.com)

Email: [info@infusioncenterne.com](mailto:info@infusioncenterne.com)

**Infusion Center of New England**

18 Washington Street, Foxboro MA 02035

Ph: 781-551-5812

Fax: 508-698-8671



**Prescribing Order: Actemra (tocilizumab) or Biosimilar**

Date of Order: \_\_\_\_\_

☐ New Start    ☐ Maintenance

Date of last infusion: \_\_\_\_\_

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ M/F: \_\_\_\_\_

Diagnosis (include ICD-10 code/s): \_\_\_\_\_

☐ NKDA    Allergies: \_\_\_\_\_

Patient Weight: \_\_\_\_\_

**Premedication:**

- |  |  |
|--|--|
| <input type="checkbox"/> Acetaminophen 1000mg PO               | <input type="checkbox"/> Diphenhydramine 25mg IV |
| <input type="checkbox"/> Loratadine 10mg or Cetirizine 10mg PO | <input type="checkbox"/> Solu-medrol 125mg IV    |
| <input type="checkbox"/> Diphenhydramine 25mg PO               | <input type="checkbox"/> Other: _____            |

**Lab Orders:**

- |  |   |
|--|---|
| <input type="checkbox"/> CBC w/diff, CMP every _____ weeks               | <input type="checkbox"/> LFTs every _____ weeks |
| <input type="checkbox"/> Lipid Panel 4-8 weeks after treatment start x 1 |   |
| <input type="checkbox"/> Other: _____                                    |   |

**Actemra Medication Order:**

- ☐ Infuse Actemra    ☐ Infuse Actemra biosimilar as required by patient's insurance

Dosing:                      ☐ 4mg/kg                      ☐ 8mg/kg                      ☐ Other: \_\_\_\_\_

Frequency:                      ☐ Every 2 weeks                      ☐ Every 4 weeks                      ☐ Other: \_\_\_\_\_

**Administration:**

- ✓ Mix Actemra or biosimilar in 100ml Normal Saline and administer intravenously over 1 hour.
- ✓ Do not administer if patient has active signs or symptoms of infection.
- ✓ HOLD tocilizumab if most recent ANC <2000, AST/ALT >1.5x normal limit, or platelets <100,000. Notify provider.
- ✓ In case of infusion reaction, STOP infusion and follow NCNE infusion reaction protocol. Notify provider.

Ordering Provider Name

NPI

Signature

Date

Infusion Center of New England

18 Washington Street, Foxboro MA 02035

Ph: 781-551-5812

Fax: 508-698-8671